Drugs / CD19/22 bispecific CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03463928 | Oct 2017 → Jun 2019 | lymphoid leukemia | Chinese PLA General Hospital | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19/22 bispecific CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03463928 ↗ |
| Action | Deplete | “CAR-T cell mediated targeted elimination of CD19 expressing B cells” NCT03463928 ↗ |
| Modality | Cell therapy | “CD19/22 bispecific CAR-T cells” NCT03463928 ↗ |
| Route | Other | “The allo-CAR-T cells will be infused in a fractionated manner” NCT03463928 ↗ |
| Target | CD19 | “donor-derived CD19/22 bispecific CAR-T cells” NCT03463928 ↗ |